Seizures absence

Succinimides. Ethosuximide [77-67-8] C2H22NO2 (41) and the related succinknide, methsuximide [77-41-8] C22H23NO2 (42) are used in absence seizure treatment. Like the other anticonvulsants discussed, the mechanism of action of the succinirnides is unclear. Effects on T-type calcium channels and -ATPase activity have been reported (20). Ethosuximide has significant CNS and gastrointestinal (GI) side effect HabiUties (13). 

Generalized seizures include absence, myoclonic, and tonic-clonic. Manifestations of a generalized tonic-clonic seizure include alternate contraction (tonic phase) and relaxation (clonic phase) of muscles, a loss of consciousness, and abnormal behavior. Myoclonic seizures involve sudden, forceful contractions involving the musculature of the trunk, neck, and extremities. Absence seizures, previously referred to as petit mal seizures, are seizures characterized by a brief loss of consciousness during which physical activity ceases. The seizures typically last a few seconds, occur many times a day, and may go unnoticed by others. 

Which statement would be included when educating the patient taking trimetiiadione for absence seizures ... 

The primary care provider prescribes ethosuximide syrup 500 mg for a patient with absence seizures. The drug is available in a strength of 250 mg/5 mL The nurse administers. ... 

Petit mal (PM) or absence seizures (AS). These are less dramatic and generally occur in children. They entail a brief and abrupt loss of awareness (consciousness) in which the patient suddenly ceases ongoing activity or speech and stares vacantly for a few seconds before recovering equally quickly. Motor disturbances are rare apart from blinking of the eyes and the patient has no recollection of the event. 

Many seizures are associated with distinctive EEG patterns (Fig. 16.1). Perhaps the most striking is the 3 per second spike wave activity seen in most leads (cortical areas) in absence seizures, which can be invoked by hyperventilation. Otherwise distinctive EEG patterns are usually only found during an actual seizure, with burst spiking seen alongside clonus in TCS and abnormal discharges with the behavioural patterns of partial epilepsy and in particular that originating in the temporal lobe. 

It has become clear that drugs which are effective in protecting mice against PTZ are effective in absence seizures while those able to control the tonic response to maximal electroshock are effective in tonic-clonic seizure. Some drugs are effective in only one test and clinical condition whilst a few are active in both (Table 16.1). Experimental focal seizures are indicative of partial seizures. 

NTs it is now appropriate to consider what evidence there is for a malfunction of NT activity in epilepsy, particularly in those responsible for primary excitation and inhibition, i.e. the amino acids. Before doing so the epileptogenesis of absence seizures (petit mal) justifies separate consideration. 

Phenobarbitone was the first AED and was introduced in 1912. It was largely replaced in 1932 by phenytoin for the management of tonic-xilonic seizures and partial and secondary epilepsy. Carbamazepine followed, then ethosuximide for absence seizures and valproic acid. These remained, apart from the introduction of the benzodiazepines, the mainstay of therapy until the last decade. They were introduced solely on their ability to control experimentally induced seizures. Their mechanisms of action were unknown and no thought was given to the possibility of NT modification and in fact subsequent research has shown that with the exception of the benzodiazepines none of them work primarily through NT manipulation. They act directly on neuronal excitability. 

Clonazepam, a typical 1 4 benzodiazepine, is effective in absence seizures, myoclonic jerks and tonic-clonic seizures and given intravenously it attenuates status epilepticus. It is less sedative than phenobarbitone but tolerance develops and its withdrawal, as... 

Introduced initially for absence seizures, this drug is now known to be effective in and used to treat tonic lonic seizures and most types of epilepsy. It was found to inhibit GABA transaminase and so elevate GABA concentrations and inhibition. This is achieved, however, over a slower time-course than its anti-seizure effect, especially experimentally, which is now thought to be due to its phenytoin-like, use-dependent block of sodium channels. Since, unlike phenytoin, the full effect of valproate takes some weeks to develop, its slower effect on GABA metabolism and activity should not be ignored. 

One unwanted side-effect of phenytoin is its anti-folate activity. A programme of synthetic chemistry to manipulate the structure of the anti-folate compound pyri-methium to try to replace that property with anticonvulsant activity resulted in the synthesis of lamotrigine. It proved to be an effective AED in partial and generalised epilepsy but experience has found it also to be of value in absence seizures. 

Juvenile myoclonic epilepsy (JME) A primary generalized epilepsy syndrome that usually starts in the early to middle teenage years and has a strong familial component. Patients have myoclonic jerks and tonic-clonic seizures and may also have absence seizures. 

Outside of the evidence-based guidelines, other pharmacologic treatments are commonly used or avoided. For initial treatment of absence seizures, ethosuximide and valproate are commonly used, not only in the United Kingdom, but also in the United States. Zonisamide may be also used for initial treatment of absence and myoclonic seizures. In absence and myoclonic seizures, carbamazepine, oxcarbazepine, gabapentin, tiagabine, and pregabalin should be avoided, as they have been associated with an exacerbation of these types of seizures. 

Valproic acid, phenytoin, carbamazine Ethosuximide, valproic acid Valproic acid Diazepam, lorazepam Grand mal seizures Absence seizures Myoclonus Status epileptic us... 

A 20-year-old male with absence seizures is treated with ethosux-imide. What is the principal mechanism of action of ethosuximide ... 

The answer is d. (Kat ung, p 408J Ethosuximide is very effective in absence seizures. Clonazepam is also effective... 

The answer is d. (Katzung, pp 408-409.) Ethosuximide is especially useful in the treatment of absence seizures Although it may act at several... 

Absence seizures have only very brief (seconds) periods of altered consciousness. 

Absence seizures generally occur in young children or adolescents and exhibit a sudden onset, interruption of ongoing activities, a blank stare, and possibly a brief upward rotation of the eyes. Absence seizures have a characteristic two to four cycle/second spike and slow-wave EEG pattern. 

Absence seizures are best treated with ethosuximide, valproic acid, and perhaps lamotrigine. For a combination of absence and other generalized or partial seizures, valproic acid is preferred. If valproic acid is ineffective in treating a mixed seizure disorder that includes absence, ethosuximide should be used in combination with another AED. 

---